Clinical Nuclear Medicine

Skip Navigation LinksHome > October 2012 - Volume 37 - Issue 10 > 11C-Methionine PET/CT and MRI of Primary Central Nervous Sys...
Clinical Nuclear Medicine:
doi: 10.1097/RLU.0b013e318252d1ea
Original Articles

11C-Methionine PET/CT and MRI of Primary Central Nervous System Diffuse Large B-cell Lymphoma Before and After High-Dose Methotrexate

Jang, Su Jin MD*; Lee, Kyung-Han MD; Lee, Ji Young MD*; Choi, Joon Young MD; Kim, Byung-Tae MD; Kim, Seok Jin MD; Kim, Won Seog MD

Collapse Box


Purpose: Although the optimum treatment of primary central nervous system lymphoma (PCNSL) remains a challenge, there is increasing interest in methotrexate-based chemotherapy as an effective strategy. Here, we report evidence supporting the utility of methionine PET/CT for evaluating PCNSL disease extent and response to high-dose methotrexate therapy.

Patients and Methods: Four patients newly diagnosed with diffuse large B-cell PCNSL underwent methionine PET/CT and MRI of the brain at baseline and again after completion of high-dose methotrexate combination chemotherapy. Three patients also received pretreatment FDG PET/CT, and the intervals between MRI and both PET/CTs were within 3 weeks. The results of methionine PET/CT were compared with MRI and clinical findings.

Results: Pretreatment methionine PET/CT demonstrated clear demarcation of PCNSL tumors with high contrast in 3 patients and only faint uptake in the remaining patient, which also showed low FDG uptake. In 1 patient, methionine PET/CT displayed more tumor lesions than FDG PET/CT did. After high-dose methotrexate chemotherapy, methionine images displayed complete disappearance of abnormal uptake in all 4 patients. In 3 of the patients, posttreatment MRI and clinical follow-up corroborated findings of complete remission. In the remaining patient, MRI showed nonenhancing T2 hyperintensities in the periventricular white matter, for which the significance was inconclusive.

Conclusions: Methionine PET/CT may provide clinically useful information complementary to MRI for monitoring the response to systemic chemotherapy in patients with PCNSL.

© 2012 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.